FDA Approval Activities for this Drug…

Diovan Tablets, Novartis NDA 020818 3/06/98 8/13/03 Diovan (valsartan) Capsules, Novartis NDA 20-665/S-004 11/27/98 Diovan (valsartan) Capsules & Tablets, Novartis NDA 21-283 7/18/01 5/5/03 8/12/03 Diovan (valsartan) Capsules & Tablets, Novartis NDA 20-665/S-016 & 21-283/S-001 8/14/02 8/21/02 8/14/02 2/3/03 Diovan (valsartan) Tablets, Novartis NDA 21-283/S-002 4/5/02 4/16/02 7/25/02 7/25/02 Diovan HCT (valsartan/hydrochlorothiazide) Tablets, 80/12.5 mg and 160/25 mg Novartis Corp. NDA 20-818/S16 1/15/03 1/23/03 7/8/03 Diovan HCT (valsartan/hydrochlorothiazide) Tablets, 80/12.5 mg and 160/12.5 mg. Novartis Corp. NDA 20-818/S12 Diovan (Valsartan) Tablet, Novartis NDA 21-283 7/18/01 Diovan Indications: Indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. | Diovan (valsartan) Tablets, Novartis Pharma, Labeling Revision

For the latest approval information, please see the main page.